Member Info for Burmesepython

Shhhhhhh Taff , I need to buy more ;-))))

Taff , this will be massive. Look at the brands now IDP own , Roots, Skinny Tan , Stevie K and others. They are rling several products out according to the last RNS. Global presence on every front. Haris Choudary owns 6M shares of the 14M in issue. TAKEOVER TARGET by one of the MAJORS!!! This is what this is being lined up for. BUY & HOLD. NO placing coming £2M in cash according to the last RNS!!

FDA approval 1st of its kind in the US. Nobody has this so nobody can sell this product except IDP. Anybody wanting to do the same will take them 10 yrs. whoop whoop.

�2M in cash held so very strong cash position. Trading very robust. 52 week share price high �4.20. Worlds leading ED product approved by the FDA.

InnovaDerma continues to perform strongly and profitably. Our online engagement continues to grow daily which is driving revenue through to our DTC platforms. We are in discussions with several new retail distributors and product innovation remains on track. The business remains robust with several product and market launches expected in the coming months to generate further growth."

Here the company has really lost all my respect here. Just no need for this at all.

The only Erectyal Dysfunction that�s been FDA approved in the US ever. It�s a British company that�s leading the innovation. Recent highs of �4.20 and the business has more top brands in a global market place inc the U.K. with the like of Boots & Superdrug etc.

They should�ve rolled this tech out then did a placing. Why now? Had the tech been rolled out & launched officially we could�ve seen 3 pence not 0.30 placing. The just raised cash a few weeks ago. This looks like more delays. Anybody looking at getting out here , look at IDP. Late runs yesterday of 1st FDA approved erectyal dysfunction drug available on the market in the US.

Owns just under 6M shares of the 14 million shares in issue. He has to deliver and the rest of the board look pretty decent with lots skin in the game.

Only 14 million shares in issue, £2M cash in the bank and the business is robust as ever. This has to be on the radar for bigger pharmas who want to get in on a product which can take many years to develop. This is why IDP have been chosen to take this to the global market. Pittance of a market cap considering we have a product that's the only FDA approved in the US. Nobody else has this so if it's good enough for the US market it sure is good enough for the rest of the world.

For lifelong sufferers of premature ejaculation, finding a permanent solution has previously been hugely costly and time consuming, with treatments limited to techniques like cognitive behavioural therapy. This has meant that many men have not been able to seek support, and have been left feeling isolated. Through this program, we're able to offer men a cost effective, permanent solution -- with no side effects -- which they can use in the privacy of their own home."

InnovaDerma PLC (LSE: IDP) specializes in the research, manufacture and marketing of clinically proven products in life sciences, beauty and personal care products. InnovaDerma has presence in Europe, US, Australasia, Asia and Africa. To find out more about Smiling Dick and the Prolong Device and Climax Control Training Program. Looks like the deal is lock stock & barrel. People have yet to digest that this is the only FDA approved PE product to be launched in the US & now being rolled out in the UK & Europe. This is a testament to the company who have been selected because they have the infrastructure in place to roll this produce out globally. This is HUGH!!!!!!

As outlined in the Company's interim results in January, the Company has now launched ProlongTM * -- the world's only FDA-cleared medical device for premature ejaculation in the United States and Australia.The launch is being supported by a highly creative marketing campaign including a website smilingdick.com, a new, first of its kind, ground-breaking sex-positive platform with the aim to normalise and de-stigmatise discussions around sexual health and wellbeing for men.

As this product is the only one approved by the FDA, so I am pretty sure the big pharma companies will be all over this pretty soon. This could be revolutionary and could roll out on a global platform. The success rates are phenomenal;-)))

Eddie, Now you got your sell you can move on from here. I'm glad I don't write about every stock I've made a little money on. This has got another 100% on this. My other stock PSL has 3 bagged already in 4 weeks. Look at my history on it you will see. Just look at W7L market cap compared to here. The new erectial dysfunction product launch will be announced soon and I and all the other holders here are anticipating solid news and progress as we move forward ;-)) Like I said 4.30 , 52 week high & placing done @ £2.76 last October. £2M ready cash in the bank. 14M shares in issue with very little free float.

& £2million cash in the bank. Business is as robust as ever. New product launch RNS will Send this into Orbit

In Auction ;-))))

Last years highs £4.30 , Placing oct last year @ £2.76 and the last trading statement was robust & upbeat Next RNS will be lift off ;-)))

The IRI data (world's largest independent data provider for Fast-Moving Consumer Goods (FMCG)) highlights that in Superdrug, Skinny Tan's revenue (including sub brand Body Glow) grew by 210% for the 52 weeks until the end of 24 February 2018 compared to the same period in the previous year. For the 12 weeks ending 24 February 2018, revenues were up 60% versus the same period last year. The Company's Direct to Consumer ("DTC") platform for Skinny Tan is performing well and in line with management expectations. The Group is in discussions with several new distribution partners for the ranging of Skinny Tan. Roots, the Company's haircare range continues to deliver strong growth through DTC and in Superdrug with online engagement rising every week across its product range. IRI data estimates that for the 12 weeks until the end of 24 February, revenues were up 254% compared to the previous 12 weeks. The Group expects revenues to be substantially higher than last year. The profit before tax is now expected to be similar to FY17 due to the significant investment made across the business over the last six months. Haris Chaudhry, Executive Chairman said "Whilst we expect our full year results to be below our earlier expectations, InnovaDerma continues to perform strongly and profitably. Our online engagement continues to grow daily which is driving revenue through to our DTC platforms. We are in discussions with several new retail distributors and product innovation remains on track. The business remains robust with several product and market launches expected in the coming months to generate further growth."

This has Rerate written all over i. Only 14M shares in issue. Global business both retail & online ;-)))